All Stories

  1. The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review

    Article • Journal of Dermatological Treatment, December 2023, Taylor & Francis

    Phyllis Spuls

  2. Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting

    Article • British Journal of Dermatology, October 2023, Oxford University Press (OUP)

    Phyllis Spuls

  3. Expanding the molecular and clinical spectrum of autosomal recessive congenital ichthyosis caused by pathogenic variants in NIPAL4 and PNPLA1 and evaluation of novel therapeutic interventions

    Article • Journal of the European Academy of Dermatology and Venereology, July 2023, Wiley

    Phyllis Spuls

  4. Reporting of Harmonising Outcome Measures for Eczema (HOME) core outcome set instruments in randomized clinical trials for systemic treatments in atopic dermatitis

    Article • British Journal of Dermatology, July 2023, Oxford University Press (OUP)

    Phyllis Spuls

  5. The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study

    Article • Journal of Dermatological Treatment, May 2023, Taylor & Francis

    Phyllis Spuls

  6. Effectiveness and patient satisfaction of a Dutch patient decision aid for psoriasis – a pilot study

    Article • Journal of Dermatological Treatment, March 2023, Taylor & Francis

    Phyllis Spuls

  7. Measurement instruments for the core outcome set of congenital melanocytic naevi and an assessment of the measurement properties according to COSMIN: a systematic review

    Article • JPRAS Open, March 2023, Elsevier

    Phyllis Spuls

  8. A core outcome domain set for clinical research on capillary malformations (the COSCAM project): an e-Delphi process and consensus meeting

    Article • British Journal of Dermatology, November 2022, Oxford University Press (OUP)

    Phyllis Spuls

  9. Appearance-related concerns and their impact on health-related quality of life in patients with peripheral vascular malformations

    Article • Journal of Plastic Reconstructive & Aesthetic Surgery, November 2022, Elsevier

    Phyllis Spuls

  10. Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review

    Article • Journal of Dermatological Treatment, September 2022, Taylor & Francis

    Phyllis Spuls

  11. Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”

    Article • Journal of the American Academy of Dermatology, September 2021, Elsevier

    Phyllis Spuls

  12. Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2*

    Article • British Journal of Dermatology, July 2021, Oxford University Press (OUP)

    Phyllis Spuls

  13. Development of a core outcome domain set for clinical research on capillary malformations (the COSCAM project)

    Article • Journal of the European Academy of Dermatology and Venereology, June 2021, Wiley

    Phyllis Spuls

  14. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series

    Article • Clinical and Experimental Dermatology, June 2021, Oxford University Press (OUP)

    Phyllis Spuls

  15. The Selection Process for a Web-Based Application to Measure Patient-Reported Outcomes Following the Example of the TREAT NL Registry

    Article • Journal of Investigative Dermatology, June 2021, Elsevier

    Phyllis Spuls

  16. Work ability and quality of working life in atopic dermatitis patients treated with dupilumab

    Article • The Journal of Dermatology, May 2021, Wiley

    Phyllis Spuls

  17. Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals

    Article • The Journal of Rheumatology, May 2021, The Journal of Rheumatology

    Phyllis Spuls

  18. Learning from disease registries during a pandemic: Moving toward an international federation of patient registries

    Article • Clinics in Dermatology, May 2021, Elsevier

    Phyllis Spuls

  19. Surgical Treatment of Peripheral Vascular Malformations: A Systematic Review and Meta-Analysis

    Article • Plastic & Reconstructive Surgery, April 2021, Wolters Kluwer Health

    Phyllis Spuls

  20. Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

    Article • Journal of the European Academy of Dermatology and Venereology, April 2021, Wiley

    Phyllis Spuls

  21. Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey*

    Article • British Journal of Dermatology, March 2021, Oxford University Press (OUP)

    Phyllis Spuls

  22. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics

    Article • Journal of the European Academy of Dermatology and Venereology, March 2021, Wiley

    Phyllis Spuls

  23. Online decision aid for patients with psoriasis

    Article • British Journal of Dermatology, March 2021, Oxford University Press (OUP)

    Phyllis Spuls

  24. Responsiveness of quality of life measures in children with peripheral vascular malformations: The OVAMA project

    Article • JPRAS Open, March 2021, Elsevier

    Phyllis Spuls

  25. Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research*

    Article • British Journal of Dermatology, March 2021, Oxford University Press (OUP)

    Phyllis Spuls

  26. Phototherapy for atopic eczema

    Article • Cochrane Database of Systematic Reviews, February 2021, Wiley

    Phyllis Spuls

  27. Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*

    Article • British Journal of Dermatology, February 2021, Oxford University Press (OUP)

    Phyllis Spuls

  28. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

    Article • Journal of the European Academy of Dermatology and Venereology, February 2021, Wiley

    Phyllis Spuls

  29. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

    Article • Journal of Allergy and Clinical Immunology, January 2021, Elsevier

    Phyllis Spuls

  30. Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach

    Article • Journal of the European Academy of Dermatology and Venereology, January 2021, Wiley

    Phyllis Spuls

  31. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

    Article • Journal of the European Academy of Dermatology and Venereology, November 2020, Wiley

    Phyllis Spuls

  32. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

    Article • Journal of the American Academy of Dermatology, November 2020, Elsevier

    Phyllis Spuls

  33. Outcome assessment in dermatology clinical trials and cochrane reviews: call for a dermatology‐specific outcome taxonomy

    Article • Journal of the European Academy of Dermatology and Venereology, September 2020, Wiley

    Phyllis Spuls

  34. International collaboration and rapid harmonization across dermatologic COVID-19 registries

    Article • Journal of the American Academy of Dermatology, September 2020, Elsevier

    Phyllis Spuls

  35. The current extent of and need for shared decision making in atopic dermatitis and psoriasis in the Netherlands: an online survey study amongst patients and physicians

    Article • Journal of the European Academy of Dermatology and Venereology, July 2020, Wiley

    Phyllis Spuls

  36. Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics

    Article • Expert Opinion on Drug Safety, July 2020, Taylor & Francis

    Phyllis Spuls

  37. Global reporting of cases of COVID‐19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic

    Article • British Journal of Dermatology, June 2020, Oxford University Press (OUP)

    Phyllis Spuls

  38. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis

    Article • Journal of the European Academy of Dermatology and Venereology, June 2020, Wiley

    Phyllis Spuls

  39. Generic outcome set for the international registry on Laser trEAtments in Dermatology (LEAD): a protocol for a Delphi study to achieve consensus on what to measure

    Article • BMJ Open, June 2020, BMJ

    Phyllis Spuls

  40. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis

    Article • JAMA Dermatology, June 2020, American Medical Association (AMA)

    Phyllis Spuls

  41. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases

    Article • Drug Safety, May 2020, Springer Science + Business Media

    Phyllis Spuls

  42. Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative

    Article • Journal of the American Academy of Dermatology, May 2020, Elsevier

    Phyllis Spuls

  43. Outcomes and measurement instruments used in congenital melanocytic naevi research: A systematic review

    Article • Journal of Plastic Reconstructive & Aesthetic Surgery, April 2020, Elsevier

    Phyllis Spuls

  44. The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate‐to‐severe atopic eczema*

    Article • British Journal of Dermatology, March 2020, Oxford University Press (OUP)

    Phyllis Spuls

  45. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema ( RECAP )

    Article • British Journal of Dermatology, February 2020, Oxford University Press (OUP)

    Phyllis Spuls

  46. Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients

    Article • Journal of the European Academy of Dermatology and Venereology, February 2020, Wiley

    Phyllis Spuls

  47. Towards More Shared Decision Making in Dermatology: Develop­ment of Evidence-based Decision Cards for Psoriasis and Atopic Eczema Treatments

    Article • Acta Dermato Venereologica, January 2020, Acta Dermato-Venereologica

    Phyllis Spuls

  48. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group

    Article • British Journal of Dermatology, December 2019, Wiley

    Helen Alexander, Phyllis Spuls

  49. Responsiveness of quality‐of‐life measures in patients with peripheral vascular malformations: the OVAMA project

    Article • British Journal of Dermatology, December 2019, Oxford University Press (OUP)

    Phyllis Spuls

  50. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema

    Article • British Journal of Dermatology, November 2019, Oxford University Press (OUP)

    Phyllis Spuls

  51. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data

    Article • British Journal of Dermatology, October 2019, Oxford University Press (OUP)

    Phyllis Spuls

  52. Protocol for the development of core set of domains of the core outcome set for patients with congenital melanocytic naevi (OCOMEN project)

    Article • Journal of the European Academy of Dermatology and Venereology, October 2019, Wiley

    Phyllis Spuls

  53. Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab

    Article • Therapeutic Drug Monitoring, October 2019, Wolters Kluwer Health

    Phyllis Spuls

  54. Outcome measurement instruments for peripheral vascular malformations and an assessment of the measurement properties: a systematic review

    Article • Quality of Life Research, September 2019, Springer Science + Business Media

    Phyllis Spuls

  55. Finalizing the international core domain set for peripheral vascular malformations: the OVAMA project

    Article • British Journal of Dermatology, July 2019, Oxford University Press (OUP)

    Phyllis Spuls

  56. Navigating the landscape of core outcome set development in dermatology

    Article • Journal of the American Academy of Dermatology, July 2019, Elsevier

    Phyllis Spuls

  57. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

    Article • Journal of the European Academy of Dermatology and Venereology, June 2019, Wiley

    Phyllis Spuls

  58. TRE atment of AT opic eczema ( TREAT ) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries

    Article • British Journal of Dermatology, June 2019, Oxford University Press (OUP)

    Phyllis Spuls

  59. Cochrane Reviews and Dermatological Trials Outcome Concordance: Why Core Outcome Sets Could Make Trial Results More Usable

    Article • Journal of Investigative Dermatology, May 2019, Elsevier

    Phyllis Spuls

  60. Highlights of the updated Dutch evidence‐ and consensus‐based guideline on psoriasis 2017

    Article • British Journal of Dermatology, January 2019, Oxford University Press (OUP)

    Phyllis Spuls

  61. Reversibility of alexithymia with effective treatment of moderate‐to‐severe psoriasis: longitudinal data from EPIDEPSO

    Article • British Journal of Dermatology, November 2018, Oxford University Press (OUP)

    Phyllis Spuls

  62. Relationship and probabilistic stratification of Eczema Area and Severity Index and objective Scoring Atopic Dermatitis severity scores for atopic dermatitis

    Article • British Journal of Dermatology, September 2018, Wiley

    Phyllis Spuls

  63. Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults

    Article • Cochrane Database of Systematic Reviews, August 2018, Wiley

    Phyllis Spuls

  64. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries

    Article • British Journal of Dermatology, August 2018, Wiley

    Professor Carsten Flohr, Phyllis Spuls

  65. Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis

    Article • BMJ Open, August 2018, BMJ

    Phyllis Spuls

  66. Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative

    Article • British Journal of Dermatology, June 2018, Wiley

    Phyllis Spuls, Masutaka Furue

  67. Patient-Reported Outcomes of Bleomycin Sclerotherapy for Low-Flow Vascular Malformations and Predictors of Improvement

    Article • CardioVascular and Interventional Radiology, June 2018, Springer Science + Business Media

    Phyllis Spuls

  68. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

    Article • British Journal of Dermatology, April 2018, Oxford University Press (OUP)

    Phyllis Spuls

  69. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial

    Article • British Journal of Dermatology, April 2018, Wiley

    Phyllis Spuls

  70. Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative

    Article • British Journal of Dermatology, April 2018, Oxford University Press (OUP)

    Phyllis Spuls

  71. By using a core outcome set we measure what matters to patients

    Article • British Journal of Dermatology, March 2018, Wiley

    Phyllis Spuls

  72. Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data

    Article • Journal of Allergy and Clinical Immunology, February 2018, Elsevier

    Phyllis Spuls

  73. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement

    Article • British Journal of Dermatology, January 2018, Wiley

    Dedee Murrell, Phyllis Spuls

  74. Development of an international core outcome set for peripheral vascular malformations: the OVAMA project

    Article • British Journal of Dermatology, January 2018, Oxford University Press (OUP)

    Phyllis Spuls

  75. Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

    Article • Acta Dermato Venereologica, January 2018, Acta Dermato-Venereologica

    Phyllis Spuls

  76. Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment

    Article • British Journal of Dermatology, November 2017, Wiley

    Phyllis Spuls

  77. Discrepancy between the clinical and histopathologic diagnosis of soft tissue vascular malformations

    Article • Journal of the American Academy of Dermatology, November 2017, Elsevier

    Phyllis Spuls

  78. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries

    Article • Journal of the European Academy of Dermatology and Venereology, October 2017, Wiley

    PhD Antonio Addis, Phyllis Spuls

  79. How to write a Critically Appraised Topic: evidence to underpin routine clinical practice

    Article • British Journal of Dermatology, October 2017, Wiley

    Phyllis Spuls

  80. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council

    Article • Journal of the American Academy of Dermatology, October 2017, Elsevier

    Phyllis Spuls

  81. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC

    Article • Journal of the European Academy of Dermatology and Venereology, September 2017, Wiley

    Phyllis Spuls

  82. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC

    Article • Journal of the European Academy of Dermatology and Venereology, September 2017, Wiley

    Phyllis Spuls

  83. Procollagen-3 N -terminal peptide measurements for the detection of liver fibrosis in methotrexate-treated patients with psoriasis: daily practice use and clinical implications

    Article • British Journal of Dermatology, September 2017, Wiley

    Marisol Otero, Phyllis Spuls

  84. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries

    Article • Journal of Investigative Dermatology, September 2017, Elsevier

    Phyllis Spuls

  85. One-stop-shop with confocal microscopy imaging vs. standard care for surgical treatment of basal cell carcinoma: an open-label, noninferiority, randomized controlled multicentre trial

    Article • British Journal of Dermatology, August 2017, Wiley

    Phyllis Spuls

  86. Reporting of outcomes in randomised controlled trials on nail psoriasis; a Systematic Review

    Article • British Journal of Dermatology, July 2017, Wiley

    Phyllis Spuls

  87. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety

    Article • British Journal of Dermatology, May 2017, Oxford University Press (OUP)

    Phyllis Spuls

  88. Doing Good Research Is Difficult, Doing No Research Is More Difficult

    Article • Journal of Investigative Dermatology, May 2017, Elsevier

    Phyllis Spuls

  89. Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study

    Article • British Journal of Dermatology, April 2017, Wiley

    Professor Luis Puig, Phyllis Spuls

  90. Pregnancy and fetal outcomes after paternal exposure to azathioprine, methotrexate or mycophenolic acid: a critically appraised topic

    Article • British Journal of Dermatology, April 2017, Oxford University Press (OUP)

    Phyllis Spuls

  91. Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial

    Article • Trials, March 2017, Springer Science + Business Media

    Phyllis Spuls

  92. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement

    Article • British Journal of Dermatology, March 2017, Wiley

    Phyllis Spuls

  93. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries

    Article • Trials, February 2017, Springer Science + Business Media

    Phyllis Spuls

  94. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study

    Article • British Journal of Dermatology, February 2017, Oxford University Press (OUP)

    Phyllis Spuls

  95. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial

    Article • Trials, February 2017, Springer Science + Business Media

    Phyllis Spuls

  96. Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries

    Article • Acta Dermato Venereologica, January 2017, Acta Dermato-Venereologica

    Dr Ignacio Garcia-Doval, Phyllis Spuls

  97. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder

    Article • Journal of Investigative Dermatology, January 2017, Elsevier

    Phyllis Spuls

  98. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field

    Article • Journal of the American Academy of Dermatology, December 2016, Elsevier

    Phyllis Spuls

  99. Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review

    Article • British Journal of Dermatology, July 2016, Oxford University Press (OUP)

    Phyllis Spuls

  100. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review

    Article • Allergy, July 2016, Wiley

    Phyllis Spuls

  101. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

    Article • British Journal of Dermatology, July 2016, Wiley

    Professor Matthew J Ridd, Phyllis Spuls

  102. Global Allergy Forum and 3rd Davos Declaration 2015

    Article • Allergy, March 2016, Wiley

    Phyllis Spuls

  103. Intralesional Bleomycin Injections for Vascular Malformations

    Article • Plastic & Reconstructive Surgery, January 2016, Wolters Kluwer Health

    Phyllis Spuls

  104. Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation

    Article • Acta Dermato Venereologica, January 2016, Acta Dermato-Venereologica

    Phyllis Spuls

  105. Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults

    Article • Cochrane Database of Systematic Reviews, November 2015, Wiley

    Phyllis Spuls

  106. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

    Article • Journal of the European Academy of Dermatology and Venereology, October 2015, Wiley

    Phyllis Spuls

  107. Diphencyprone treatment in patients with alopecia areata

    Article • British Journal of Dermatology, October 2015, Wiley

    Dr Rosanna Kuin, Dr Esther J van Zuuren, Phyllis Spuls

  108. The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial

    Article • British Journal of Dermatology, August 2015, Oxford University Press (OUP)

    Phyllis Spuls

  109. In vivo confocal microscopy of basal cell carcinoma: a systematic review of diagnostic accuracy

    Article • Journal of the European Academy of Dermatology and Venereology, August 2015, Wiley

    Phyllis Spuls

  110. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting

    Article • British Journal of Dermatology, August 2015, Oxford University Press (OUP)

    Phyllis Spuls

  111. Clearing up misunderstandings around core outcomes for atopic dermatitis

    Article • British Journal of Dermatology, July 2015, Oxford University Press (OUP)

    Phyllis Spuls

  112. Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis

    Article • JAMA Dermatology, June 2015, American Medical Association (AMA)

    Phyllis Spuls

  113. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres

    Article • Journal of the European Academy of Dermatology and Venereology, March 2015, Wiley

    Phyllis Spuls

  114. Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

    Article • Journal of Clinical Oncology, March 2015, American Society of Clinical Oncology (ASCO)

    Phyllis Spuls

  115. A national study on adherence to a basal cell carcinoma guideline; development of a tool to assess guideline adherence

    Article • British Journal of Dermatology, February 2015, Oxford University Press (OUP)

    Phyllis Spuls

  116. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal

    Article • British Journal of Dermatology, January 2015, Wiley

    Phyllis Spuls

  117. Health-related Quality of Life in Patients with Cutaneous Rosacea: A Systematic Review

    Article • Acta Dermato Venereologica, January 2015, Acta Dermato-Venereologica

    Phyllis Spuls

  118. The Harmonizing Outcome Measures for Eczema (HOME) Roadmap: A Methodological Framework to Develop Core Sets of Outcome Measurements in Dermatology

    Article • Journal of Investigative Dermatology, January 2015, Elsevier

    Phyllis Spuls

  119. The IL-17A-Producing CD8 + T-Cell Population in Psoriatic Lesional Skin Comprises Mucosa-Associated Invariant T Cells and Conventional T Cells

    Article • Journal of Investigative Dermatology, December 2014, Elsevier

    Phyllis Spuls

  120. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)

    Article • British Journal of Dermatology, November 2014, Wiley

    Dr. Jasvinder A. Singh, Phyllis Spuls

  121. Combined Use of Systemic Agents for Psoriasis

    Article • JAMA Dermatology, November 2014, American Medical Association (AMA)

    Phyllis Spuls

  122. Prospective registration of clinical trials published in the B ritish J ournal of D ermatology

    Article • British Journal of Dermatology, October 2014, Oxford University Press (OUP)

    Phyllis Spuls

  123. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials

    Article • Journal of Allergy and Clinical Immunology, October 2014, Elsevier

    Dr. Jasvinder A. Singh, Phyllis Spuls

  124. An increased risk of non‐melanoma skin cancer during TNF‐inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease‐related factors

    Article • Journal of the European Academy of Dermatology and Venereology, September 2014, Wiley

    Phyllis Spuls

  125. Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR + ILC3 in Lesional Skin and Blood of Psoriasis Patients

    Article • Journal of Investigative Dermatology, September 2014, Elsevier

    Phyllis Spuls

  126. Prioritizing dermatoses: rationally selecting guideline topics

    Article • Journal of the European Academy of Dermatology and Venereology, August 2014, Wiley

    Phyllis Spuls

  127. Critically Appraised Topics in the British Journal of Dermatology : response from Jonathan Batchelor and Phyllis Spuls, section editors for BJD 's ‘Put...

    Article • British Journal of Dermatology, August 2014, Oxford University Press (OUP)

    Phyllis Spuls

  128. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single‐centre database analysis

    Article • British Journal of Dermatology, August 2014, Oxford University Press (OUP)

    Phyllis Spuls

  129. Treatment of Psoriasis

    Article • June 2014, Wiley

    Phyllis Spuls

  130. Evaluation of a Tertiary Teledermatology Service Between Peripheral and Academic Dermatologists in The Netherlands

    Article • Telemedicine and e-Health, April 2014, Mary Ann Liebert Inc

    Phyllis Spuls

  131. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research

    Article • British Journal of Dermatology, March 2014, Oxford University Press (OUP)

    Phyllis Spuls

  132. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review

    Article • Journal of Allergy and Clinical Immunology, February 2014, Elsevier

    Phyllis Spuls

  133. Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis

    Article • JAMA Dermatology, February 2014, American Medical Association (AMA)

    Phyllis Spuls

  134. Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation

    Article • Journal of Allergy and Clinical Immunology, December 2013, Elsevier

    Phyllis Spuls

  135. Comment on ‘Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study’

    Article • British Journal of Dermatology, October 2013, Oxford University Press (OUP)

    Phyllis Spuls

  136. The European treatment of severe atopic eczema in children taskforce (TREAT) survey

    Article • British Journal of Dermatology, October 2013, Oxford University Press (OUP)

    Phyllis Spuls

  137. Accuracy and reliability of teledermatoscopy with images taken by general practitioners during everyday practice

    Article • Journal of Telemedicine and Telecare, September 2013, SAGE Publications

    Phyllis Spuls

  138. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries

    Article • British Journal of Dermatology, August 2013, Wiley

    Dr Ignacio Garcia-Doval, Professor Marcus Schmitt-Egenolf, Phyllis Spuls

  139. House dust mite reduction in the management of atopic dermatitis. A critically appraised topic

    Article • British Journal of Dermatology, March 2013, Oxford University Press (OUP)

    Phyllis Spuls

  140. Interventions for nail psoriasis

    Article • Cochrane Database of Systematic Reviews, January 2013, Wiley

    Phyllis Spuls

  141. The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: study protocol for a multicenter randomized controlled trial

    Article • Trials, December 2012, Springer Science + Business Media

    Phyllis Spuls

  142. Measurement Properties of Outcome Measures for Vitiligo

    Article • Archives of Dermatology, November 2012, American Medical Association (AMA)

    Phyllis Spuls

  143. The prevalence of thyroid disease in patients with vitiligo: a systematic review

    Article • British Journal of Dermatology, October 2012, Oxford University Press (OUP)

    Phyllis Spuls

  144. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal

    Article • British Journal of Dermatology, September 2012, Oxford University Press (OUP)

    Phyllis Spuls

  145. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting

    Article • Allergy, July 2012, Wiley

    Phyllis Spuls

  146. Health-Related Quality-of-Life Assessment in Dermatologic Practice: Relevance and Application

    Article • Dermatologic Clinics, April 2012, Elsevier

    Phyllis Spuls

  147. Response to a randomized trial of methotrexate vs. azathioprine for severe atopic eczema: a critical appraisal

    Article • British Journal of Dermatology, March 2012, Oxford University Press (OUP)

    Phyllis Spuls

  148. Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies

    Article • Dermatology, January 2012, Karger Publishers

    Dr Ignacio Garcia-Doval, Professor Marcus Schmitt-Egenolf, Phyllis Spuls

  149. Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review

    Article • British Journal of Dermatology, November 2011, Oxford University Press (OUP)

    Phyllis Spuls

  150. Teledermatology applied following patient selection by general practitioners in daily practice improves efficiency and quality of care at lower cost

    Article • British Journal of Dermatology, November 2011, Oxford University Press (OUP)

    Phyllis Spuls

  151. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men

    Article • JDDG Journal der Deutschen Dermatologischen Gesellschaft, October 2011, Wiley

    Phyllis Spuls

  152. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference

    Article • Allergy, September 2011, Wiley

    Phyllis Spuls

  153. A randomized trial of methotrexate versus azathioprine for severe atopic eczema

    Article • Journal of Allergy and Clinical Immunology, August 2011, Elsevier

    Phyllis Spuls

  154. A randomized comparison of excimer laser versus narrow‐band ultraviolet B phototherapy after punch grafting in stable vitiligo patients

    Article • Journal of the European Academy of Dermatology and Venereology, June 2011, Wiley

    Phyllis Spuls

  155. Survival in cancer patients hospitalized for psoriasis: a commentary

    Article • British Journal of Dermatology, June 2011, Oxford University Press (OUP)

    Phyllis Spuls

  156. Prospective comparison of three guideline development methods for treatment of actinic keratosis

    Article • BMJ Quality & Safety, May 2011, BMJ

    Phyllis Spuls

  157. Off-label Use of Azathioprine in Dermatology

    Article • Archives of Dermatology, April 2011, American Medical Association (AMA)

    Phyllis Spuls

  158. Validation and refinement of the Millennium Criteria for atopic dermatitis

    Article • The Journal of Dermatology, March 2011, Wiley

    Phyllis Spuls

  159. Etanercept

    Article • Archives of Dermatology, January 2011, American Medical Association (AMA)

    Phyllis Spuls

  160. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges

    Article • Journal of the European Academy of Dermatology and Venereology, November 2010, Wiley

    Phyllis Spuls

  161. A pilot study on tertiary teledermatology: feasibility and acceptance of telecommunication among dermatologists

    Article • Journal of Telemedicine and Telecare, October 2010, SAGE Publications

    Phyllis Spuls

  162. Evaluation of and Perspectives on Guidelines: What Is Important?

    Article • Journal of Investigative Dermatology, October 2010, Elsevier

    Phyllis Spuls

  163. Off-label use of efalizumab in dermatology

    Article • Expert Review of Dermatology, October 2010, Taylor & Francis

    Phyllis Spuls

  164. Definition of treatment goals for moderate to severe psoriasis: a European consensus

    Article • Archives of Dermatological Research, September 2010, Springer Science + Business Media

    Dr. MD. PhD Flora Balieva, Phyllis Spuls

  165. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept

    Article • British Journal of Dermatology, July 2010, Oxford University Press (OUP)

    Phyllis Spuls

  166. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot

    Article • British Journal of Dermatology, May 2010, Oxford University Press (OUP)

    Phyllis Spuls

  167. How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review

    Article • Journal of Investigative Dermatology, April 2010, Elsevier

    Phyllis Spuls

  168. Is there a rural/urban gradient in the prevalence of eczema? A systematic review

    Article • British Journal of Dermatology, March 2010, Oxford University Press (OUP)

    Phyllis Spuls

  169. Atopic eczema or atopiform dermatitis

    Article • Experimental Dermatology, March 2010, Wiley

    Phyllis Spuls

  170. Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis

    Article • Archives of Dermatology, February 2010, American Medical Association (AMA)

    Phyllis Spuls

  171. Tertiary Teledermatology: A Systematic Review

    Article • Telemedicine and e-Health, February 2010, Mary Ann Liebert Inc

    Phyllis Spuls

  172. Experience with biologics for psoriasis in daily practice: switching is worth a try

    Article • British Journal of Dermatology, October 2009, Oxford University Press (OUP)

    Phyllis Spuls

  173. The burden of vitiligo: Patient characteristics associated with quality of life

    Article • Journal of the American Academy of Dermatology, September 2009, Elsevier

    Phyllis Spuls

  174. The Misperception That Clinical Trial Data Reflect Long-term Drug Safety

    Article • Archives of Dermatology, September 2009, American Medical Association (AMA)

    Phyllis Spuls

  175. A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: ‘AGREE-ing’ on a common base for European evidence-based psoriasis treatment guidelines

    Article • Journal of the European Academy of Dermatology and Venereology, July 2009, Wiley

    Phyllis Spuls

  176. Interventions for nail psoriasis

    Article • January 2009, Wiley

    Phyllis Spuls

  177. STROBE

    Article • Archives of Dermatology, September 2008, American Medical Association (AMA)

    Phyllis Spuls

  178. Topical treatments in psoriasis: today and tomorrow

    Article • Clinics in Dermatology, September 2008, Elsevier

    Phyllis Spuls

  179. Controversies in Atopic Dermatitis

    Article • Dermatitis, July 2008, Wolters Kluwer Health

    Phyllis Spuls